Zhiwei Zhong
P.R. China
Guangzhou, 510000, China
Guangzhou, 510000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.
Journal: Molecular biomedicine
Published: January 28, 2026
SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia.
Journal: NPJ precision oncology
Published: November 01, 2025
Inflammatory Cytokines May Mediate the Causal Relationship between Metabolites and Primary Sclerosing Cholangitis: A Bidirectional Mediation Mendelian Randomization Study.
Journal: Current medicinal chemistry
Published: October 01, 2025
mROS‑calcium feedback loop promotes lethal ventricular arrhythmias and sudden cardiac death in early myocardial ischemia.
Journal: International journal of molecular medicine
Published: August 02, 2023
Chromosomal Aberrations in Pediatric Patients With Moderate/Severe Developmental Delay/Intellectual Disability With Abundant Phenotypic Heterogeneities: A Single-Center Study.
Journal: Pediatric neurology
Published: March 16, 2023
A novel prognostic 7-methylguanosine signature reflects immune microenvironment and alternative splicing in glioma based on multi-omics analysis.
Journal: Frontiers in cell and developmental biology
Published: March 23, 2022
Sirtuin 1 knockdown inhibits glioma cell proliferation and potentiates temozolomide toxicity via facilitation of reactive oxygen species generation.
Journal: Oncology letters
Published: February 07, 2018
Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas.
Journal: Cancer epidemiology
Published: May 24, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026